Clinical trial · no report yet · Phase 3
LIBERTAS
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
- NCT05884398 ↗
- Active not recruiting
- Janssen Research & Development, LLC
- 36 commentary sources found
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| X threads | 21 | |
| YouTube | 10 | |
| Podcasts | 5 |
The trial
ClinicalTrials.gov- Official title
- A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide With Continued Versus Intermittent Androgen-Deprivation Therapy (ADT) Following PSA Response in Participants With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Metastatic Castrate-sensitive Prostate Cancer
- Interventions
- Apalutamide; Androgen-deprivation Therapy (ADT)
- Arms
- Arm A (Intermittent ADT Group) · Experimental
- Arm B (Continuous ADT Group) · Active comparator
- Enrollment
- 420
- Primary outcomes
- Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)
- Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months
- Sponsor
- Janssen Research & Development, LLC
- Start
- Aug 31, 2023
- Primary completion
- Oct 12, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05884398 · updated Sep 25, 2026